Allogenic human purified pancreatic islets — Competitive Intelligence Brief

Allogenic human purified pancreatic islets (Allogenic human purified pancreatic islets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy. Area: Endocrinology / Diabetes.

phase 3 Cell therapy Endocrinology / Diabetes Biologic

Target snapshot

Allogenic human purified pancreatic islets (Allogenic human purified pancreatic islets) — National Institute of Allergy and Infectious Diseases (NIAID). Allogenic human purified pancreatic islets restore insulin-producing beta cell function by transplanting functional islet cells into patients with type 1 diabetes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Allogenic human purified pancreatic islets TARGET	Allogenic human purified pancreatic islets	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	Cell therapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
RAK therapy	RAK therapy	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Cell therapy
Licartin and CIK	Licartin and CIK	Tianjin Medical University Cancer Institute and Hospital	marketed	Monoclonal antibody (Licartin); Adoptive cell therapy (CIK)	HAb18G/CD147 antigen (Licartin); Multiple (CIK cells)
Mesenchymal Stem Cells (MSCs)	Mesenchymal Stem Cells (MSCs)	The Cleveland Clinic	marketed	Cell therapy
Cord Blood Cell	Cord Blood Cell	China Spinal Cord Injury Network	marketed	Cell therapy
Cord blood	Cord blood	New York Medical College	marketed	Hematopoietic stem cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy class)

1. Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León · 2 drugs in this class
2. Bone Therapeutics S.A · 1 drug in this class
3. DiscGenics, Inc. · 1 drug in this class
4. Celavie Bioscences, LLC · 1 drug in this class
5. China Spinal Cord Injury Network · 1 drug in this class
6. City of Hope Medical Center · 1 drug in this class
7. Brainstorm-Cell Therapeutics · 1 drug in this class
8. Dr. Grant M. Pagdin · 1 drug in this class
9. FDA Office of Orphan Products Development · 1 drug in this class
10. Biosolution Co., Ltd. · 1 drug in this class